Short description of BioVersys' TRIC Technology
BioVersys has developed an innovative new technology that enables the company screen, identify and develop molecules that switch off bacterial resistance mechanisms. This technology comprises several modules and has been termed “TRIC”, which is short for Transcriptional Regulator Inhibitory Compounds. Aiming at the intracellular pathways responsible for bacterial resistance, our approach is based on the identification and inactivation of bacterial resistance mechanisms in relevant pathogens.
One of our lead series already exhibited excellent characteristics in rendering multi-resistant Mycobacterium tuberculosis sensitive again to the classical antibiotic prodrug ethionamide. Currently, we are expanding our screening and compound portfolio to nosocomial bacterial strains (e.g. Pseudomonas aeruginosa, Enterococcus faecium or Acinetobacter baumannii) that contribute not only to the escalating costs of healthcare but also cause high numbers of casualties worldwide.